Abstract
Oncologic imaging has been a major focus of clinical research on PET/MR over the last 10 years. Studies so far have shown that PET/MR with 18F-Fluorodeoxyglucose (FDG) overall provides a similar accuracy for tumor staging as FDG PET/CT. The effective radiation dose of whole-body FDG PET/MR is more than 50% lower than for FDG PET/CT, making PET/MR particularly attractive for imaging of children. However, the longer acquisition times and higher costs have so far limited broader clinical use of PET/MR technology for whole-body staging. With the currently available technology, PET/MR appears more promising for locoregional staging of diseases for which MR is the anatomical imaging modality of choice. These include brain tumors, head and neck cancers, gynecologic malignancies, and prostate cancer. For instance, PET imaging with ligands of prostate-specific membrane antigen, combined with multi-parametric MR, appears promising for detection of prostate cancer and differentiation from benign prostate pathologies as well as for detection of local recurrences. The combination of functional parameters from MR, such as apparent diffusion coefficients, and molecular parameters from PET, such as receptor densities or metabolic rates, is feasible in clinical studies, but clinical applications for this multimodal and multi-parametric imaging approach still need to be defined.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Bailey DL, Barthel H, Beyer T, Boellaard R, Guckel B, Hellwig D et al (2013) Summary report of the first international workshop on PET/MR imaging, March 19–23, 2012, Tubingen, Germany. Mol Imaging Biol 15:361–371
Bailey DL, Antoch G, Bartenstein P, Barthel H, Beer AJ, Bisdas S et al (2015) Combined PET/MR: the real work has just started. In: Summary report of the third international workshop on PET/MR imaging, 17–21 February 2014, Tubingen, Germany. Mol Imaging Biol 17:297–312
Grueneisen J, Schaarschmidt BM, Heubner M, Suntharalingam S, Milk I, Kinner S et al (2015) Implementation of FAST-PET/MRI for whole-body staging of female patients with recurrent pelvic malignancies: a comparison to PET/CT. Eur J Radiol 84:2097–2102
Grueneisen J, Sawicki LM, Schaarschmidt BM, Suntharalingam S, von der Ropp S, Wetter A et al (2016) Evaluation of a fast protocol for staging lymphoma patients with integrated PET/MRI. PLoS ONE 11:e0157880
Grueneisen J, Sawicki LM, Wetter A, Kirchner J, Kinner S, Aktas B et al (2017) Evaluation of PET and MR datasets in integrated 18F-FDG PET/MRI: a comparison of different MR sequences for whole-body restaging of breast cancer patients. Eur J Radiol 89:14–19
Kirchner J, Sawicki LM, Suntharalingam S, Grueneisen J, Ruhlmann V, Aktas B et al (2017) Whole-body staging of female patients with recurrent pelvic malignancies: ultra-fast 18F-FDG PET/MRI compared to 18F-FDG PET/CT and CT. PLoS ONE 12:e0172553
Spick C, Herrmann K, Czernin J (2016) 18F-FDG PET/CT and PET/MRI perform equally well in cancer: evidence from studies on more than 2,300 patients. J Nucl Med 57:420–430
Kuhn FP, Hullner M, Mader CE, Kastrinidis N, Huber GF, von Schulthess GK et al (2014) Contrast-enhanced PET/MR imaging versus contrast-enhanced PET/CT in head and neck cancer: how much MR information is needed? J Nucl Med 55:551–558
Hayashi K, Kikuchi M, Imai Y, Yamashita D, Hino M, Ito K et al (2019) Clinical value of fused PET/MRI for surgical planning in patients with oral/oropharyngeal carcinoma. Laryngoscope
Kubiessa K, Purz S, Gawlitza M, Kuhn A, Fuchs J, Steinhoff KG et al (2014) Initial clinical results of simultaneous 18F-FDG PET/MRI in comparison to 18F-FDG PET/CT in patients with head and neck cancer. Eur J Nucl Med Mol Imaging 41:639–648
Platzek I (2016) (18)F-Fluorodeoxyglucose PET/MR imaging in head and neck cancer. PET Clin 11:375–386
Schaarschmidt BM, Heusch P, Buchbender C, Ruhlmann M, Bergmann C, Ruhlmann V et al (2016) Locoregional tumour evaluation of squamous cell carcinoma in the head and neck area: a comparison between MRI, PET/CT and integrated PET/MRI. Eur J Nucl Med Mol Imaging 43:92–102
Sekine T, de Galiza Barbosa F, Kuhn FP, Burger IA, Stolzmann P, Huber GF et al (2017) PET + MR versus PET/CT in the initial staging of head and neck cancer, using a trimodality PET/CT + MR system. Clin Imaging 42:232–239
Szyszko TA, Cook GJR (2018) PET/CT and PET/MRI in head and neck malignancy. Clin Radiol 73:60–69
Hope TA, Pampaloni MH, Nakakura E, VanBrocklin H, Slater J, Jivan S et al (2015) Simultaneous (68)Ga-DOTA-TOC PET/MRI with gadoxetate disodium in patients with neuroendocrine tumor. Abdom Imaging 40:1432–1440
Kirchner J, Sawicki LM, Deuschl C, Gruneisen J, Beiderwellen K, Lauenstein TC et al (2017) 18 F-FDG PET/MR imaging in patients with suspected liver lesions: value of liver-specific contrast agent Gadobenate dimeglumine. PLoS ONE 12:e0180349
Mayerhoefer ME, Ba-Ssalamah A, Weber M, Mitterhauser M, Eidherr H, Wadsak W et al (2013) Gadoxetate-enhanced versus diffusion-weighted MRI for fused Ga-68-DOTANOC PET/MRI in patients with neuroendocrine tumours of the upper abdomen. Eur Radiol 23:1978–1985
Lee DH, Lee JM, Hur BY, Joo I, Yi NJ, Suh KS et al (2016) Colorectal cancer liver metastases: diagnostic performance and prognostic value of PET/MR imaging. Radiology 280:782–792
Reiner CS, Stolzmann P, Husmann L, Burger IA, Hullner MW, Schaefer NG et al (2014) Protocol requirements and diagnostic value of PET/MR imaging for liver metastasis detection. Eur J Nucl Med Mol Imaging 41:649–658
Beiderwellen K, Geraldo L, Ruhlmann V, Heusch P, Gomez B, Nensa F et al (2015) Accuracy of [18F]FDG PET/MRI for the detection of liver metastases. PLoS ONE 10:e0137285
Sawicki LM, Kirchner J, Grueneisen J, Ruhlmann V, Aktas B, Schaarschmidt BM et al (2018) Comparison of (18)F-FDG PET/MRI and MRI alone for whole-body staging and potential impact on therapeutic management of women with suspected recurrent pelvic cancer: a follow-up study. Eur J Nucl Med Mol Imaging 45:622–629
Grueneisen J, Nagarajah J, Buchbender C, Hoffmann O, Schaarschmidt BM, Poeppel T et al (2015) Positron emission tomography/magnetic resonance imaging for local tumor staging in patients with primary breast cancer: a comparison with positron emission tomography/computed tomography and magnetic resonance imaging. Invest Radiol 50:505–513
Pace L, Nicolai E, Luongo A, Aiello M, Catalano OA, Soricelli A et al (2014) Comparison of whole-body PET/CT and PET/MRI in breast cancer patients: lesion detection and quantitation of 18F-deoxyglucose uptake in lesions and in normal organ tissues. Eur J Radiol 83:289–296
Botsikas D, Kalovidouri A, Becker M, Copercini M, Djema DA, Bodmer A et al (2016) Clinical utility of 18F-FDG-PET/MR for preoperative breast cancer staging. Eur Radiol 26:2297–2307
Botsikas D, Bagetakos I, Picarra M, Da Cunha Afonso Barisits AC, Boudabbous S, Montet X et al (2019) What is the diagnostic performance of 18-FDG-PET/MR compared to PET/CT for the N- and M- staging of breast cancer? Eur Radiol 29:1787–1798
Wang J, Shih TT, Yen RF (2017) Multiparametric evaluation of treatment response to neoadjuvant chemotherapy in breast cancer using integrated PET/MR. Clin Nucl Med 42:506–513
Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH et al (2018) MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med 378:1767–1777
Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK et al (2017) Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet 389:815–822
Lindenberg ML, Turkbey B, Mena E, Choyke PL (2017) Imaging locally advanced, recurrent, and metastatic prostate cancer: a review. JAMA Oncol 3:1415–1422
Rosenkrantz AB, Ginocchio LA, Cornfeld D, Froemming AT, Gupta RT, Turkbey B et al (2016) Interobserver reproducibility of the PI-RADS version 2 Lexicon: a multicenter study of six experienced prostate radiologists. Radiology 280:793–804
Li M, Huang Z, Yu H, Wang Y, Zhang Y, Song B (2019) Comparison of PET/MRI with multiparametric MRI in diagnosis of primary prostate cancer: a meta-analysis. Eur J Radiol 113:225–231
Eiber M, Weirich G, Holzapfel K, Souvatzoglou M, Haller B, Rauscher I et al (2016) Simultaneous (68)Ga-PSMA HBED-CC PET/MRI improves the localization of primary prostate cancer. Eur Urol 70:829–836
Al-Bayati M, Grueneisen J, Lutje S, Sawicki LM, Suntharalingam S, Tschirdewahn S et al (2018) Integrated 68Gallium labelled prostate-specific membrane antigen-11 positron emission tomography/magnetic resonance imaging enhances discriminatory power of multi-parametric prostate magnetic resonance imaging. Urol Int 100:164–171
Taneja S, Jena A, Taneja R, Singh A, Ahuja A (2018) Effect of combined (68)Ga-PSMAHBED-CC uptake pattern and multiparametric MRI derived with simultaneous PET/MRI in the diagnosis of primary prostate cancer: initial experience. AJR Am J Roentgenol 210:1338–1345
Hicks RM, Simko JP, Westphalen AC, Nguyen HG, Greene KL, Zhang L et al (2018) Diagnostic accuracy of (68)Ga-PSMA-11 PET/MRI compared with multiparametric MRI in the detection of prostate cancer. Radiology 289:730–737
Jambor I, Kuisma A, Kahkonen E, Kemppainen J, Merisaari H, Eskola O et al (2018) Prospective evaluation of (18)F-FACBC PET/CT and PET/MRI versus multiparametric MRI in intermediate- to high-risk prostate cancer patients (FLUCIPRO trial). Eur J Nucl Med Mol Imaging 45:355–364
Jena A, Taneja R, Taneja S, Singh A, Kumar V, Agarwal A et al (2018) Improving diagnosis of primary prostate cancer with combined (68)Ga-Prostate-Specific Membrane Antigen-HBED-CC simultaneous PET and multiparametric MRI and clinical parameters. AJR Am J Roentgenol 211:1246–1253
Lee MS, Cho JY, Kim SY, Cheon GJ, Moon MH, Oh S et al (2017) Diagnostic value of integrated PET/MRI for detection and localization of prostate cancer: comparative study of multiparametric MRI and PET/CT. J Magn Reson Imaging 45:597–609
Park SY, Zacharias C, Harrison C, Fan RE, Kunder C, Hatami N et al (2018) Gallium 68 PSMA-11 PET/MR imaging in patients with intermediate- or high-risk prostate cancer. Radiology 288:495–505
de Perrot T, Rager O, Scheffler M, Lord M, Pusztaszeri M, Iselin C et al (2014) Potential of hybrid (1)(8)F-fluorocholine PET/MRI for prostate cancer imaging. Eur J Nucl Med Mol Imaging 41:1744–1755
Muehe AM, Theruvath AJ, Lai L, Aghighi M, Quon A, Holdsworth SJ et al (2018) How to provide gadolinium-free PET/MR cancer staging of children and young adults in less than 1 h: the Stanford approach. Mol Imaging Biol 20:324–335
Siegel JA, Pennington CW, Sacks B (2017) Subjecting radiologic imaging to the linear no-threshold hypothesis: a non sequitur of non-trivial proportion. J Nucl Med 58:1–6
Weber W, Zanzonico P (2017) The controversial linear no-threshold model. J Nucl Med 58:7–8
Kwatra NS, Lim R, Gee MS, States LJ, Vossough A, Lee EY (2019) PET/MR imaging: current updates on pediatric applications. Magn Reson Imaging Clin N Am 27:387–407
Schneuer FJ, Bentley JP, Davidson AJ, Holland AJ, Badawi N, Martin AJ et al (2018) The impact of general anesthesia on child development and school performance: a population-based study. Paediatr Anaesth 28:528–536
Platzek I, Beuthien-Baumann B, Schneider M, Gudziol V, Kitzler HH, Maus J et al (2014) FDG PET/MR for lymph node staging in head and neck cancer. Eur J Radiol 83:1163–1168
Chan SC, Yeh CH, Yen TC, Ng SH, Chang JT, Lin CY et al (2018) Clinical utility of simultaneous whole-body (18)F-FDG PET/MRI as a single-step imaging modality in the staging of primary nasopharyngeal carcinoma. Eur J Nucl Med Mol Imaging 45:1297–1308
Kanda T, Kitajima K, Suenaga Y, Konishi J, Sasaki R, Morimoto K et al (2013) Value of retrospective image fusion of (18)F-FDG PET and MRI for preoperative staging of head and neck cancer: comparison with PET/CT and contrast-enhanced neck MRI. Eur J Radiol 82:2005–2010
Beiderwellen K, Grueneisen J, Ruhlmann V, Buderath P, Aktas B, Heusch P et al (2015) [(18)F]FDG PET/MRI vs. PET/CT for whole-body staging in patients with recurrent malignancies of the female pelvis: initial results. Eur J Nucl Med Mol Imaging 42:56–65
Grueneisen J, Beiderwellen K, Heusch P, Gratz M, Schulze-Hagen A, Heubner M et al (2014) Simultaneous positron emission tomography/magnetic resonance imaging for whole-body staging in patients with recurrent gynecological malignancies of the pelvis: a comparison to whole-body magnetic resonance imaging alone. Invest Radiol 49:808–815
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Weber, W. (2020). Clinical PET/MR. In: Schober, O., Kiessling, F., Debus, J. (eds) Molecular Imaging in Oncology. Recent Results in Cancer Research, vol 216. Springer, Cham. https://doi.org/10.1007/978-3-030-42618-7_22
Download citation
DOI: https://doi.org/10.1007/978-3-030-42618-7_22
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-42617-0
Online ISBN: 978-3-030-42618-7
eBook Packages: MedicineMedicine (R0)